123 related articles for article (PubMed ID: 28676869)
1. Impact of the biomolecular corona on the structure of PEGylated liposomes.
Digiacomo L; Pozzi D; Amenitsch H; Caracciolo G
Biomater Sci; 2017 Aug; 5(9):1884-1888. PubMed ID: 28676869
[TBL] [Abstract][Full Text] [Related]
2. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study.
Hadjidemetriou M; McAdam S; Garner G; Thackeray C; Knight D; Smith D; Al-Ahmady Z; Mazza M; Rogan J; Clamp A; Kostarelos K
Adv Mater; 2019 Jan; 31(4):e1803335. PubMed ID: 30488990
[TBL] [Abstract][Full Text] [Related]
3. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona.
Caracciolo G
Nanoscale; 2018 Mar; 10(9):4167-4172. PubMed ID: 29450412
[TBL] [Abstract][Full Text] [Related]
4. The protein corona of circulating PEGylated liposomes.
Palchetti S; Colapicchioni V; Digiacomo L; Caracciolo G; Pozzi D; Capriotti AL; La Barbera G; Laganà A
Biochim Biophys Acta; 2016 Feb; 1858(2):189-96. PubMed ID: 26607013
[TBL] [Abstract][Full Text] [Related]
5. Multi-parametric surface plasmon resonance platform for studying liposome-serum interactions and protein corona formation.
Kari OK; Rojalin T; Salmaso S; Barattin M; Jarva H; Meri S; Yliperttula M; Viitala T; Urtti A
Drug Deliv Transl Res; 2017 Apr; 7(2):228-240. PubMed ID: 27491413
[TBL] [Abstract][Full Text] [Related]
6. Variations in metabolite profiles of serum coronas produced around PEGylated liposomal drugs by surface property.
Jang GJ; Jeong JY; Joung H; Han SY
Colloids Surf B Biointerfaces; 2023 Oct; 230():113488. PubMed ID: 37574616
[TBL] [Abstract][Full Text] [Related]
7. Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.
Papi M; Caputo D; Palmieri V; Coppola R; Palchetti S; Bugli F; Martini C; Digiacomo L; Pozzi D; Caracciolo G
Nanoscale; 2017 Jul; 9(29):10327-10334. PubMed ID: 28702661
[TBL] [Abstract][Full Text] [Related]
8. Functionalization of Liposomes with Hydrophilic Polymers Results in Macrophage Uptake Independent of the Protein Corona.
Weber C; Voigt M; Simon J; Danner AK; Frey H; Mailänder V; Helm M; Morsbach S; Landfester K
Biomacromolecules; 2019 Aug; 20(8):2989-2999. PubMed ID: 31268685
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles.
Hadjidemetriou M; Al-Ahmady Z; Mazza M; Collins RF; Dawson K; Kostarelos K
ACS Nano; 2015 Aug; 9(8):8142-56. PubMed ID: 26135229
[TBL] [Abstract][Full Text] [Related]
10. Opsonin-Deficient Nucleoproteic Corona Endows UnPEGylated Liposomes with Stealth Properties
Giulimondi F; Vulpis E; Digiacomo L; Giuli MV; Mancusi A; Capriotti AL; Laganà A; Cerrato A; Zenezini Chiozzi R; Nicoletti C; Amenitsch H; Cardarelli F; Masuelli L; Bei R; Screpanti I; Pozzi D; Zingoni A; Checquolo S; Caracciolo G
ACS Nano; 2022 Feb; 16(2):2088-2100. PubMed ID: 35040637
[TBL] [Abstract][Full Text] [Related]
11. Effect of Glucose on Liposome-Plasma Protein Interactions: Relevance for the Physiological Response of Clinically Approved Liposomal Formulations.
Palchetti S; Digiacomo L; Pozzi D; Zenezini Chiozzi R; Capriotti AL; Laganà A; Coppola R; Caputo D; Sharifzadeh M; Mahmoudi M; Caracciolo G
Adv Biosyst; 2019 Feb; 3(2):e1800221. PubMed ID: 32627369
[TBL] [Abstract][Full Text] [Related]
12. In situ analysis of liposome hard and soft protein corona structure and composition in a single label-free workflow.
Kari OK; Ndika J; Parkkila P; Louna A; Lajunen T; Puustinen A; Viitala T; Alenius H; Urtti A
Nanoscale; 2020 Jan; 12(3):1728-1741. PubMed ID: 31894806
[TBL] [Abstract][Full Text] [Related]
13. Deciphering the monocyte-targeting mechanisms of PEGylated cationic liposomes by investigating the biomolecular corona.
Münter R; Bak M; Thomsen ME; Parhamifar L; Stensballe A; Simonsen JB; Kristensen K; Andresen TL
Int J Pharm; 2024 May; 657():124129. PubMed ID: 38621615
[TBL] [Abstract][Full Text] [Related]
14. Tuning liposome composition to modulate corona formation in human serum and cellular uptake.
Yang K; Mesquita B; Horvatovich P; Salvati A
Acta Biomater; 2020 Apr; 106():314-327. PubMed ID: 32081780
[TBL] [Abstract][Full Text] [Related]
15. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells.
Pozzi D; Colapicchioni V; Caracciolo G; Piovesana S; Capriotti AL; Palchetti S; De Grossi S; Riccioli A; Amenitsch H; Laganà A
Nanoscale; 2014 Mar; 6(5):2782-92. PubMed ID: 24463404
[TBL] [Abstract][Full Text] [Related]
16. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
Hadjidemetriou M; Al-Ahmady Z; Kostarelos K
Nanoscale; 2016 Apr; 8(13):6948-57. PubMed ID: 26961355
[TBL] [Abstract][Full Text] [Related]
17. Amphiphilic dendrimers control protein binding and corona formation on liposome nanocarriers.
Wagner J; Dillenburger M; Simon J; Oberländer J; Landfester K; Mailänder V; Ng DYW; Müllen K; Weil T
Chem Commun (Camb); 2020 Aug; 56(61):8663-8666. PubMed ID: 32608398
[TBL] [Abstract][Full Text] [Related]
18. Unveiling the in Vivo Protein Corona of Circulating Leukocyte-like Carriers.
Corbo C; Molinaro R; Taraballi F; Toledano Furman NE; Hartman KA; Sherman MB; De Rosa E; Kirui DK; Salvatore F; Tasciotti E
ACS Nano; 2017 Mar; 11(3):3262-3273. PubMed ID: 28264157
[TBL] [Abstract][Full Text] [Related]
19. PEGylated Liposomes as Carriers of Hydrophobic Porphyrins.
Dzieciuch M; Rissanen S; Szydłowska N; Bunker A; Kumorek M; Jamróz D; Vattulainen I; Nowakowska M; Róg T; Kepczynski M
J Phys Chem B; 2015 Jun; 119(22):6646-57. PubMed ID: 25965670
[TBL] [Abstract][Full Text] [Related]
20. Effects of the protein corona on liposome-liposome and liposome-cell interactions.
Corbo C; Molinaro R; Taraballi F; Toledano Furman NE; Sherman MB; Parodi A; Salvatore F; Tasciotti E
Int J Nanomedicine; 2016; 11():3049-63. PubMed ID: 27445473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
